← Back to all signals
RESEARCH PAPER ANALYSIS

Meibum Lipid Saturation Related to Dry Eye, Age, and Sex Using Nuclear Magnetic Resonance Spectroscopy.

This NMR study reports that meibum lipid hydrocarbon unsaturation decreases with age and is ~35% lower in cohorts with dry eye, Sjögren's syndrome, graft-versus-host disease, and Parkinson's disease compared with a non–dry-eye cohort.

PMID41910524
JournalInvestigative ophthalmology & visual science
Publication Date2026-03-02
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

This NMR study reports that meibum lipid hydrocarbon unsaturation decreases with age and is ~35% lower in cohorts with dry eye, Sjögren's syndrome, graft-versus-host disease, and Parkinson's disease compared with a non–dry-eye cohort.

WHY IT MATTERS

Research significance

Limited direct value for Parkinson's therapeutic discovery—the finding hints at peripheral lipid/tear-film changes in PD that might serve as exploratory biomarkers or prompt study of systemic lipid metabolism, but it offers no mechanistic targets or actionable therapeutic leads.

ABSTRACT

Source abstract

PURPOSE: The degree of unsaturation in hydrocarbon chains (HCunsat) is likely to play an important role in determining the stability, order, and fluidity of lipids in the tear film lipid layer. The HCunsat of meibum lipids was investigated in relationship with age, sex, dry eye, Sjögren's syndrome, Parkinson's disease, and treatment for allogeneic hematopoietic stem cell transplantation. METHODS: Meibum was expressed and HCunsat was measured using 1H-NMR resonances at 5.33 and 2.00 ppm. HCunsat levels were normalized to the level of wax esters, cholesteryl esters, and hydrocarbons. RESULTS: HCunsat levels, normalized to lipid esters, were found to be 20% to 40% lower in individuals aged >50 years compared with those <50 years (P < 0.05) and showed a linear age-dependent decrease with age (P < 0.001). No substantial changes were observed with sex and race, except for a 24% reduction in a small Hispanic group (P = 0.0078) compared with Caucasians. A cohort with dry eye had a ∼13% lower level of HCunsat, whereas cohorts susceptible to dry eye such as those with Sjögren's syndrome, Parkinson's, and graft-versus-host disease had a ∼35% lower HCunsat levels compared with a cohort without dry eye (P < 0.05). Experimental deviations were minimal (<4%). CONCLUSIONS: Meibum HCunsat decreases with age and is lower with dry eye, Sjögren's syndrome, and Parkinson's disease cohorts compared with a cohort without dry eye. This decrease in HCunsat is expected to contribute to lipid aggregation, decreased lipid spreading, and meibomian gland outflow. ¹H-NMR was effective for quantifying major meibum lipids.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic